{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-101073","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.854919+00:00","generated_at":"2026-05-15T14:51:26.694475+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon","bullets":["Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.","Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).","Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.","Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.","Proceeds for general corporate purposes; closing expected March 16, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-101073","json":"https://secwatch.observer/filing/0001193125-26-101073.json","markdown":"https://secwatch.observer/filing/0001193125-26-101073.md","text":"https://secwatch.observer/filing/0001193125-26-101073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/0001193125-26-101073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/crsp-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:51:26.694475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}